Company Information
CIN
Status
Date of Incorporation
19 April 2004
State / ROC
Delhi / ROC Delhi
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 June 2023
Paid Up Capital
286,128,700
Authorised Capital
400,000,000
Directors
Matangi Gowrishankar
Director/Designated Partner
over 2 years ago
over 2 years ago
Amit Varma
Director/Designated Partner
over 2 years ago
over 2 years ago
Basant Kumar Singh
Director/Designated Partner
over 2 years ago
over 2 years ago
Sandeep Jain
Director/Designated Partner
over 2 years ago
over 2 years ago
Sumeet Sood
Director/Designated Partner
over 2 years ago
over 2 years ago
Nand Lal Kalra
Director/Designated Partner
over 2 years ago
over 2 years ago
Kewal Kundanlal Handa
Director/Designated Partner
over 2 years ago
over 2 years ago
Sanjeev Jain
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Dharamvir Malik
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Neena Vivek
Director/Designated Partner
about 10 years ago
about 10 years ago
Jitendra Sharma
Additional Director
almost 15 years ago
almost 15 years ago
Past Directors
Deepak Gurudas Haldankar
Additional Director
about 5 years ago
about 5 years ago
Vinod Raheja
Cfo(kmp)
about 5 years ago
about 5 years ago
Narendra Sachdeva Dev
Director
over 8 years ago
over 8 years ago
Vijaypal Singh Rawat
Whole Time Director
about 10 years ago
about 10 years ago
Rajesh Vohra
Director
over 11 years ago
over 11 years ago
Santosh Kumar Talwar
Additional Director
over 17 years ago
over 17 years ago
Ashok Jha
Company Secretary
over 18 years ago
over 18 years ago
Dharam Chand Jain
Director
over 21 years ago
over 21 years ago
Patents
The present invention is related to a pharmaceutical composition comprising a benzodiazepine derivative having sedative/hypnotic effect with antispasmodic drug for the treatment of spasm related GERD. The benzodiazepine derivative having sedative/hypnotic effect is preferably Chlordiazepoxide and the anti¬spasmodic ...
A pharmaceutical formulation comprising Ornidazole or its pharmaceutically acceptable salt, present in the range 150 mg to 500 mg, preferably 500mg, and racecadotril or its pharmaceutically acceptable salt, present in the range 75 mg to 250 mg, more preferably 100 mg, useful for managing diarrhoea due to bacterial i...
The present invention is related to a topical.formulation for pain management. Further, the present invention relates to formulation comprising herbal ingredients. The present invention discloses a stable formulation and manufacturing method thereof which is used in the management of pain without any side effects.
...
The present invention relates to the pharmaceutical composition comprising an aminoglycoside and the protectants which reduces the Nephrotoxicity and ototoxicity.
The present invention discloses a pharmaceutical formulation comprising Cefuroxime and ofloxacin for the treatment of variety of bacterial infections. The present invention exhibits a broad spectrum activity, thereby effective against a number of microorganisms.
The present invention relates to an innovation of a pharmaceutical formulation. Further, the
present invention discloses a pharmaceutical formulation comprising Diclofenac in an injectable
dosage form. Furthermore, the present invention describes the method to manufacture a stable,
high concentration Diclofenac i...
A pharmaceutical formulation comprising Fluconazole and bioavailability enhancers, along with pharmaceutically acceptable excipients. The bioavailability enhancers piperine, curcumin, and beta cyclodextrin.
The present invention discloses a pharmaceutical formulation comprising Cefpodoxime and Roxithromycin for the treatment of variety of bacterial infections. The present invention exhibits a broad spectrum activity, thereby effective against a number of microorganisms.
The present invention relates to the formulation of the parenteral
preparation containing the NSAlDs of arylalkanoic acid class containing
pharmaceutically accepted salts of the active ingredients, suitable
solvent for dissolving the active ingredients, the preservative for
preserving the solution, the other exc...
The present invention discloses a pharmaceutical formulation comprising Amoxicillin, Clavulanic acid and Ornidazole for the treatment of variety of bacterial infections. The present invention exhibits a broad spectrum activity, thereby effective against a number of microorganisms.
A pharmaceutical formulation comprising Ofloxacin or its pharmaceutically acceptable salt, present in the range 50 mg to 250 mg, preferably 100 mg to 200 mg, and racecadotril or its pharmaceutically acceptable salt, present in the range 75 mg to 250 mg, more preferably 100 mg, useful for managing diarrhoea due to ba...
The present invention discloses a pharmaceutical formulation comprising Levofloxacin and Azithromycin for the treatment of variety of bacterial infections. The present invention exhibits a broad spectrum activity, thereby effective against a number of microorganisms.
A pharmaceutical formulation comprising 50 mg to 400 mg of Cefpodoxime, preferably 100 to 400 mg, and Levofloxacin 100 mg to 600 mg, preferably 250 to 550 mg, along with pharmaceutically acceptable excipients; useful for the treatment of a variety of bacterial infections.
The present invention is related to a novel and stable pharmaceutical formulation comprising anti-inflammatory, antipyretic having lesser side effects. The side effects of anti-inflammatory drugs are reduced by the addition of H+/K+ ATPase inhibitor. Further, the formulation is made in a unique tablet-in-tablet tech...
The present invention is related to a Ayurvedic formulation comprising
Khatika Churna (Calcium Carbonate) in the suspension, powder and in
the form of chewable tablets. The invention provides the patient
compliance by providing the formulation in various flavors as well as
excluding out the gritty nature of khat...
The present invention is related to an Effervescent Pharmaceutical formulation, comprising Sildenafil that increases chances of pregnancy during in-vitro fertilization (IVF) technique and for improving Female Sexual Dysfunctioning (FSD).
The present invention discloses a pharmaceutical formulation comprising Cefixime and ofloxacin for the treatment of variety of bacterial infections. The present invention exhibits a broad spectrum activity, thereby effective against a number of microorganisms.
The present invention relates to the pharmaceutical composition comprising the combination of lornoxicam and diacerein, which provide the patients a better and faster relief from osteoarthritic pain. The composition can be applied to symptomatic treatments of various febrile illnesses, various arthritises and inflam...
The present invention discloses a pharmaceutical formulation comprising Cefpodoxime and Ofloxacin for the treatment of variety of bacterial infections. The present invention exhibits a broad spectrum activity, thereby effective against a number of microorganisms.
The present invention encompasses a synergistic herbal combination, comprising of seven ingredients that together act for the treatment of human beings to ease constipation, add bulk to stool, corrects bowel movement and maintains intestinal bacterial flora. The seven ingredients are commercially available for the h...
The present invention discloses a pharmaceutical formulation comprising Cefpodoxime and Azithromycin for the treatment of variety of bacterial infections. The present invention exhibits a broad spectrum activity, thereby effective against a number of microorganisms.
The present invention relates to a novel pharmaceutical dosage formulation of the combination of Aceclofenac and Paracetamol, which is used for the treatment of pain and inflammation. The effervescent dosage formulation may be in the form of Powder, granules or tablets.
The present invention relates to the pharmaceutical formulation comprising at least an
estrogen, at least a progestogen and L-methyl folate calcium. Further, the estrogen is
preferably estradiol and the preferable progestogen is Nomegestrol Acetate. The
invention is also related to a combipack comprising 28 table...
The present invention is related to a topical formulation for the management of oral
ulcers. Further, the present invention discloses a topical formulation of Rebamipide for
oral ulcer along with pharmaceutical excipients. The present invention also describes a
topical formulation of rebamipide in combination wit...
The present invention discloses a pharmaceutical formulation comprising a nano-particle
system. The active ingredient of the present invention is preferably difluprednate and the nanoparticle
system has the particle size of less than 400 nm preferably 200 nm to 400 nm: The
present invention is used to administer ...
The present invention is related to the combination of Metformin and Ursodeoxycholic acid (UDCA) for the treatment of fatty liver disease. It comprises Metformin in the range of 50mg to 1500mg, preferably 200mg to 1000mg, more preferably 250 mg to 500mg and Ursodeoxycholic acid in the range of 50 mg to 1500 mg, pref...
The present invention is related to a pharmaceutical formulation comprising calcium carbonate and higher dose of vitamin D3 for the treatment of bone related disorders.
The present invention is related to a novel adjuvant formulation for the patients suffering from Neuropathic pain. The present formulation comprises of Vitamins as well as antioxidant which shows a synergistic effect in neuropathic pain.
The present invention is related to a pharmaceutical formulation of
Pantoprazole, which provides higher bioavailability and fast action than
the conventional Pantoprazole formulations.
The present invention relates to the pharmaceutical dosage form comprising
a cephalosporin and a quinolone with a beta lactamase inhibitor, which
shows the synergistic effect against the infection caused by a variety of
microorganisms.
The present invention relates to the pharmaceutical composition used for the patients having iron deficiency. The iron supplement used in the present combination is highly bioavailable having lesser side effects. The present invention also comprises Methylcobalamin, folic acid and Zinc.
The present invention discloses a oral supplement and an adjuvant therapy, which is used in the management of various liver disorders. Further, the invention consists of only nutraceutical ingredients, thus making the therapy free from side effects.
The present invention is related to administer Paracetamol & Metronidazole through Intra venous route through an aqueous vehicle. The Paracetamol & Metronidazole is dissolved in Water for Injection with the help of Passive Ingredients responsible for Buffers, Isotonic, etc. The process is done at different temperatu...
The present invention is related to administer Paracetamol & Ofloxacin through Intra venous route through an aqueous vehicle. The Paracetamol & Ofloxacin is dissolved in Water for Injection with the help of Passive Ingredients responsible for Bufers, Isotonic, etc. The process is done at different temperatures. The ...
The present invention is related to administer Paracetamol & Diclofenac Sodium through Intra venous route through an aqueous vehicle. The Paracetamol & Diclofenac Sodium is dissolved in Water for Injection with the help of Passive Ingredients responsible for Buffers, Isotonic, etc. The process is done at different t...
The present invention discloses a pharmaceutical formulation comprising Cefixime and Azithromycin for the treatment of variety of bacterial infections. The present invention exhibits a broad spectrum activity, thereby effective against a number of microorganisms.
The present invention is related to administer Paracetamol & Ciprofloxacin through Intra venous route through an aqueous vehicle. The Paracetamol & Ciprofloxacin is dissolved in Water for Injection with the help of Passive Ingredients responsible for Bufers, Isotonic, etc. The process is done at different temperatur...
The present invention discloses a pharmaceutical formulation comprising Cefixime and Levofloxacin for the treatment of variety of bacterial infections. The present invention exhibits a broad spectrum activity, thereby effective against a number of microorganisms.
The present invention relates to a novel pharmaceutical dosage formulation of cefixime, which is used for the treatment of bacterial infections with lesser side effects. The effervescent dosage formulation of cefixime may be in the form of Powder, granules or tablets.
The invention relates to a needle assembly comprising: a cannula hub defining a chamber; an inlet cannula defining an axis and having a distal end and a lumen extending therethrough, the inlet cannula being mounted to the cannula hub such that the distal end of the inlet cannula is external of the cannula hub and su...
A method of treating respiratory disease in a human suffering from an allergic and/or inflammatory condition which comprises administering to such human in need of such treating an effective amount of acebrophyline, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of Olopatadine...
The invention is related to the field of pharmaceuticals. More in particular, the present invention is related to the pharmaceutical composition comprising at least a statin, with coenzyme Q-10 and vitamin D3.
The present invention is related to administer Paracetamol through Intra venous route through an aqueous vehicle. The Paracetamol is dissolved in Water for Injection with the help of Passive Ingredients responsible for Buffers, Isotonic, etc. The process is done at different temperatures. The activity of Paracetamol...
The present invention discloses the stable and impurity free, stable, high concentration parenteral formulation of the arylalkanoic acid class of NSAIDs. The invention also discloses the method for preparing the formulation by using the suitable solvents, preservatives and other excipients.
The present invention is directed to a pharmaceutical formulation comprising ibuprofen and tizanidine along with the various excipients that are used to increase the bioavailability of the active ingredients.
The Present invention relates to the novel and synergistic pharmaceutical composition comprising [7(s)-(la,2(3,43,5a,7(3)]-9-butyl-7-(3-hydroxy- l-oxo-2-phenylpropoxy)-9-methyl-3-oxa-9-azonitricyclo[3.3.1.0(2,4)]nonane or the pharmaceutically accepted salts and 2-(2,3-dimethylphenyl) aminobenzoic acid, with an absor...
The present invention discloses a pharmaceutical formulation comprising Cefixime and Roxithromycin for the treatment of variety of bacterial infections. The present invention exhibits a broad spectrum activity, thereby effective against a number of microorganisms.
The present invention is related to a nutraceutical composition comprising Boswellia serrata Extract (Standardized to contain 70%AKBA), Zingiber officinale (Standardized to contain 5% gingerol), Curcuma longa (Standardized to contain 95 % Curcumin), Ocimum sanctum Extract (Standardized to contain 2.5% Ursolic acid),...
The present invention relates to nutraceutical based composition comprising Vitamin A (as palmitate), Vitamin C (as Ascorbic acid), Vitamin D (as Cholecalciferol), Tocotrienol , Vitamin B1( as Thiamin hydrochloride), Vitamin B2(as Riboflavin), Niacin (as Niacinamide), L-methylfolate, Vitamin B12 (as Methylcobalamin)...
ABSTRACT
The present invention discloses a pharmaceutical formulation comprising Levosulpiride and Hyoscine butyl bromide for the treatment of spasm related GERD.
The present invention discloses a pharmaceutical combination for the treatment of gastric disorders.
A pharmaceutical formulation comprising at least an antipyretic, at least an NSAID and the substances used to treat the gastric disorders. The antipyretic used is paracetamol and the NSAID is mefenamic acid. The substances used to treat gastric disorders can be Simethicone, dimethicone, or dill oil or MPS either alo...
A pharmaceutical formulation, useful for the treatment of asthma and airway inflammation due to allergy and other pathological condition, comprising Acebrophylline, Monteleukast and Levocetirizine with pharmaceutically acceptable excipients.
The present invention relates to the pharmaceutical composition comprising an aminoglycoside preferably amikacin and the protectant, preferably N-Acetyl Cysteine which reduces the toxicity of amikacin.
The present invention is directed to a pharmaceutical formulation comprising Dapoxetine and Tramadol to treat premature ejaculation. The pharmaceutical formulation comprising 15 mg to 80 mg of Dapoxtine, preferably 30 to 60 mg, and Tramadol 25 mg to 125 mg, preferably 50 to 100 mg, along with pharmaceutically accept...
The present invention is related to the pharmaceutical formulation comprising Vitamin E with increased bioavailability. The bioavailability of Vitamin E is increased by adding Sesame oil (til oil).
A pharmaceutical formulation comprising Ofloxacin or its pharmaceutically acceptable salt is present in the range 50 mg to 250 mg, preferably 100 mg to 200 mg, Ornidazole or its pharmaceutically acceptable salt, present in the range 150 mg to 500 mg, preferably 500mg, and racecadotril or its pharmaceutically accepta...
The present invention discloses an oral supplement containing Saw palmetto Extract, Green tea Extract, Nettle root Extract, Lycopene, Vitamin B6, Zinc, Vitamin B3, Vitamin B5, Biotin, Calcium and Magnesium, used for the prevention and as adjuvant therapy in androgenetic alopecia (male pattern baldness).
...
The present invention relates to a stable pharmaceutical formulation
comprising progesterone with an aqueous base, which is ready to inject.
The injection formulated is free from oil and thus will not cause irritation
at the site of injection.
The present invention relates to a pharmaceutical formulation comprising
progesterone in a lyophilized form, which on mixing with suitable liquid
solvent is ready to inject. The constituted formulation remains stable up
to a suitable period.
The present invention relates to the pharmaceutical dosage form comprising a cephalosporin preferably Cefixime and amoxicillin with a beta lactamase inhibitor, which shows the synergistic effect against the infection caused by a variety of microorganisms.
The ayurvedic formulation comprising Boswellia serrata extract, Curcuma longa, Zingiber officinale, Celery seed extract, Piperine extract and Colchicum luteum for the management of gout and related symptoms.
The present invention is related to a Herbal formulation indicated in the treatment of cough and associated disorders. The present formulation comprises of Adhatoda vasica, Glycyrrhiza glabra, Ocimum sanctum, Alpinia galanga, Cinnamonium zeylanicum, Terminalia belerica, Abies webbiana, Curcuma longa, Pistacia intege...
The invention is related to the field of pharmaceuticals. More in particular, the present invention is related to the pharmaceutical composition comprising at least a statin with coenzyme Q-10.
The present invention discloses a pharmaceutical formulation comprising Gemifloxacin and Roxithromycin for the treatment of variety of bacterial infections. The present invention exhibits a broad spectrum activity, thereby effective against a number of microorganisms.
The present invention relates to a pharmaceutical formulation for the management of symptoms of Osteoarthritis. More preferably, the formulation is used in the management of pain and stiffness due to joint degeneration. The present formulation can be formulated in various dosage forms such as tablets, capsules, sach...
The present invention relates to pharmaceutical formulations comprising ready to use cephalosporin suspension. The present invention also describes the process of formulating such formulations. Further, the preferable suspension is formulated without the use of water so as to protect the cephalosporin from accelerat...
The present invention discloses a pharmaceutical formulation comprising Azelaic acid for the treatment of acne. The invention further describes the method of preparation of the formulation. The invention relates to a topical formulation containing Azelaic acid in micronized or nanonized form.
The present invention is related to a formulation used in the management of GERD (Gastro
Esophageal Reflux Disease). Further, the present invention is related to a long acting
formulation containing proton pump inhibitor (PPI). Further, the present invention is related to a
long acting formulation containing a pr...
The present invention is describes a stable multilayered enteric coated dosage forms and process for preparation thereof. The pharmaceutical composition described herein are hard or soft shell capsules comprising polyunsaturated fatty acids useful as nutritional supplements or for the treatment of cardiovascular dis...
The present invention relates to a stable, extended-release, oral composition of metformin and a Dipeptidyl peptidase (DPP)-IV inhibitor in the form of bilayer tablets. The dual-release composition comprising an extended release (ER) layer comprising metformin or a pharmaceutically acceptable salt thereof, and one o...
The invention relates to an ophthalmic composition comprising fixed dose combination of NSAIDs and fluoroquinolone antibiotic for the treatment of ocular disorders and process of preparation thereof. In particular, an ophthalmic formulation of present invention is an aqueous solution of nepafenac and moxifloxacin h...
The invention relates to an ophthalmic composition comprising fixed dose combination of NSAIDs and fluoroquinolone antibiotic for the treatment of ocular disorders and process of preparation thereof. In particular, an ophthalmic formulation of present invention is an aqueous solution of nepafenac and moxifloxacin h...
The present invention provides a liquid composition comprising effective amount of Hydroxyurea for oral administration. The invention further discloses liquid formulation in form of ready to use oral suspension which remains stable at room temperature at the time of dispensing, storage and even after reopening of th...
The invention is related to an oral controlled osmotic drug delivery system comprising antidepressant wherein the controlled osmotic delivery system is an oral controlled porous osmotic drug delivery system. The present invention provides a simple and controlled porous osmotic drug delivery system without the need t...
The present invention related to a synergistic anti-depressant composition comprising combination of NMDA receptor antagonist and Vitamin D and process for preparation thereof. In particular, the composition of present invention is an oral nutraceutical composition which can be used as a potential supplement for ame...
The present invention provides an oral nutraceutical composition comprising synergistic combination of polyphenol and dipeptide to prevent second injuries resulting from spinal cord injury wherein the polyphenol is Curcumin and is L- carnosine. The oral nutraceutical composition is a solid dosage form which prevent ...
The present invention relates to optimized cost-efficient pharmaceutical composition and process of preparation thereof. The present invention provides a pharmaceutical composition with reduced excipient load comprising at-least one or more active ingredient and pharmaceutically acceptable excipient wherein the size...
The present invention relates to oral pharmaceutical composition comprising prazole as an active ingredient and wherein the composition exhibits dual drug release profile. The dual release composition of the present invention provides two separate individual solid units, wherein the two individual units are a solid ...
The present invention provides a nutraceutical composition for effective management of male infertility wherein the nutraceutical composition comprising blend of 15 essential male fertility nutrients which improves sperm count, sperm morphology and sperm motility. The present invention provides a unique formula of 1...
The present invention discloses a pharmaceutical composition for oral administration comprising a first solid pharmaceutical composition containing Aspirin in targeted release form and second solid pharmaceutical composition containing progesterone in sustained release form, wherein the first and the second pharmace...
The present invention discloses a topical composition comprising triple combinations of Hyaluronic acid (HA), NSAIDs and local anesthetic for effective treatment of mouth ulcers wherein NSAIDs is Choline Salicylate and local anesthetic is Lignocaine or pharmaceutical acceptable salts thereof. The triple combination ...
The present invention provides an ophthalmic composition comprising fixed dose combinations of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s) wherein the composition is free of benzalkonium chloride (BAK). The ophthalmic composition of the present invention provides a stable aqueous ophthalmic com...
The present invention relates to pharmaceutical composition comprising a Vitamin D compound including its pro-drug, metabolites and precursors wherein vitamin D is Cholecalciferol and the composition further comprises a novel solubilizing agent mixture, wherein the novel mixture of solubilizing agents comprises of h...
The invention discloses ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a Loteprednol Etabonate for treatment of post-operative inflammation and pain following ocular surgery and for dry eyes. In aspects, 5 the compositions are stable suspensions, which maintain physical sta...
The present invention relates to tablet in tablet formulation comprising an inner core tablet having Proton pump inhibitor as an active ingredient and outer shell having Prokinetic agents as an active ingredient wherein outer shell have a bi-layer structure of immediate release and sustained release comprising Proki...
The present invention provides a stable pharmaceutical composition comprising fixed dose combinations of Diclofenac and Camylofin or pharmaceutical acceptable salts thereof wherein pharmaceutical composition is an Inlay tablet formulation. Inlay tablet of present invention comprises an inner core and an outer core w...
The present invention provides a novel drug delivery system designed to simplify and enhance the treatment of angina. The novel drug delivery system of present invention is a single capsule encapsulating two sustained release tablet comprising trimetazidine. Significantly, both the first tablet and the second tablet...
The present invention provides a fixed dose combination of Omeprazole and Domperidone in a single solid dosage form, wherein the formulation comprises immediate release Domperidone and delayed release Omeprazole for effective management of Gastro-intestinal disorder. The present invention related to multi-layer pell...
The present invention relates to an improved process for the preparation of Avibactam and its pharmaceutically acceptable salts thereof. The present invention discloses a process for the preparation of Avibactam sodium of Formula I using novel intermediate of Formula V. Preferably, the present invention relates to a...
The present invention relates to a novel drug delivery system comprising Dydrogesterone wherein the novel dosage form is administered in parenteral form and provides a stable drug delivery system for rapid onset of action and improved bioavailability. The present novel dosage form provides a stable parenteral formul...
The present invention provides a novel mixtures of solubilizing agent for the solubilization of poorly water soluble pharmaceutically active agents. Moreover, the present invention provides a pharmaceutical composition comprising poorly water soluble active agent and novel mixture of solubilizing agent.
...
The present invention provides a stable pharmaceutical composition comprising fixed dose combination of doxylamine succinate and pyridoxine hydrochloride for effective treatment of nausea vomiting in pregnancy wherein the stable dosage form is a tablet-in-tablet formulation. The tablet-in-tablet dosage form of the p...
The present invention provides a composition for supplementing agents that aids in the recovery from neuropathic pain wherein the composition is a nutraceutical composition. The nutraceutical composition of present invention comprises synergistic combinations of Ubiquinone and Palmitoylethanolamide and one or more a...
The present invention provides an oral care composition for oral hygiene wherein the oral composition is in form of mouth wash. The mouth wash of the present invention comprises chlorhexidine gluconate, fluoride and Zinc salts wherein the composition further comprises hyaluronic acid. The mouth wash of the present i...
The present invention discloses an antibiotic pharmaceutical composition for the treatment of antibiotic resistant infection wherein pharmaceutical composition is a synergistic combination of antibiotic with Diazabicycloocatane â–lactamase 5 inhibitor and one or more antibacterial potentiator/enhancers. The Diazabic...
The present invention provides an oral care composition comprising synergistic combination of triple occluding/ desensitizing agents for effective treatment of hypersensitivity in teeth. The oral care composition comprises synergistic combination of oxalate salts, amino acids and fluoride salts wherein the compositi...
The present invention relates to an oral composition comprising combination of Dydrogesterone and Progesterone as a separate formulation preferably in combi-kit form. The composition of the present invention is a novel drug delivery system which avoid drawbacks associated with current prescribed regimen and dosage f...
ABSTRACT
The present invention relates to a novel drug delivery system comprising synergistic combination of Cetirizine and Minoxidil or pharmaceutically salts thereof for effective management of androgenetic alopecia wherein the synergistic combination is formulated as topical dosage form. The topical formulatio...
The present invention relates to a pharmaceutical composition comprising Ursodeoxycholic acid (UDCA) wherein the composition exhibits dual release of UDCA and pharmaceutical composition is a solid oral dosage form. The present invention provides a composition which exhibits immediate and extended drug release profil...
The present invention provides a composition for supplementing agents that aids in the recovery from neuropathic pain. The present composition provide a composition for supplementing endogenous lipids that aids the recovery from neuropathic pain, wherein the endogenous lipids are selected from N-(2-Hydroxyethyl)hex...
The present invention provides an ophthalmic composition comprising NSAIDs wherein the ophthalmic composition is free from preservatives such as benzalkonium chloride (BAK), polyquad, stabilized oxychloro complex (SOC) and sodium perborate which are known to cause cytotoxicity to ocular tissue. The ophthalmic compo...
The present invention addresses unmet needs in the field of dietary supplements and nutraceutical by providing a novel liquid shot formulation that delivers a synergistic combination of essential nutrients with enhanced bioavailability. This innovation has
the potential to improve the overall health and well-bein...
The present invention provides an oral solid composition comprising effective amount of Hydroxyurea more particularly to a dry syrup composition. The dry syrup of present invention is reconstituted with water or other suitable diluent prior to administration to form an ingestible formulation which have extended she...
The present invention relates to a stable oral formulation comprising effective amount of Cholecalciferol wherein the formulation is free from water and oil. The present invention provides a process for preparation of such oral formulation wherein the process comprising of solubilizing cholecalciferol in tocophersol...
The present invention provides a pharmaceutical formulation comprising a synergistic combination of Lobeglitazone and UDCA for the treatment of NASH and NAFLD by addressing multiple aspects of the disease simultaneously. This dual-action approach may provide improved therapeutic outcomes, potentially leading to bett...
The present invention provides a topical formulation comprising Dimethindene
maleate more particularly topical lotion. The topical lotion is applied locally on the
affected skin to reduce symptomatic itching, inflammation associated with skin
reactions such as sun burn, insect bites, dermatitis, skin rashes, ...
The present invention provides a pharmaceutical composition comprising synergistic combination of Clascoterone, minoxidil or pharmaceutical acceptable salts thereof in combination with prostaglandin analog more particularly Latanoprost. The fixed dose combination of Clascoterone, minoxidil and Latanoprost with diffe...
The present invention provides a stable composition of an aqueous solution comprising combination of ibuprofen and paracetamol or pharmaceutically acceptable salts thereof with one more anti-oxidants other than cysteine or Acetyl cysteine. The formulation further comprises buffering system comprising optionally one ...
The present invention provides a more flexible and patient-friendly dosage form comprising Hydroxyurea in a range from 50mg to 1000mg wherein the patient-friendly dosage form is in the form of a dispersible tablet which further comprises break lines. Pediatric patients, in particular, may face difficulties in swallo...
The present invention related to a pharmaceutical composition comprising fixed dose combinations of Type 2 diabetes therapeutic agents more particularly to oral formulation comprising fixed dose combinations of Sitagliptin, Voglibose and
Metformin. The oral formulation is a bi-layer tablet formulation comprising d...
The present invention provides a stable topical gel formulation comprising effective amount of Minocycline hydrochloride and a suitable base which is oil free, fat free, alcohol free and non-greasy and have improved feel when applied topically and provide a method of treating acne. The topical gel aims at utilizing ...
The present invention relates to an oral composition comprising fixed dose combination of Dydrogesterone and Progesterone in a single unit dosage form wherein oral composition is a solid unit dosage form. The composition of the present invention is a novel drug delivery system which avoid drawbacks associated with c...
ABSTRACT
TRIPLE LAYER TABLET FORMULATION OF TELMISARTAN
The present invention provides a trilayer tablet formulation containing telmisartan in an immediate release form, along with two additional antihypertensive agents in immediate or extended release forms, addresses the critical challenges of chemical incompa...
This invention relates to a process for the preparation of Cefuroxime of Formula I or pharmaceutically acceptable salts thereof. Specifically, the present invention discloses a process for the preparation of Cefuroxime sodium of Formula II which is essentially free of color impurities. More preferably, the present i...
The present invention relates to a rapidly disintegrating or dispersible tablet composition comprising Lasmiditan or its pharmaceutically acceptable salts. This composition quickly disperses in water, ensuring a faster onset of action and offering an improved therapeutic option for patients requiring immediate relie...
The present invention provides an orodispersible formulation comprising Dydrogesterone or pharmaceutically acceptable salts thereof. The orodispersible formulation is a tablet dosage form which is an alternative to conventional marketed tablet. It provides rapid disintegration, can easily be administered to Dysphagi...
Registered Trademarks
[Class : 5] Medicinal And Pharmaceutical Preparations
[Class : 5] Medicinal And Pharmaceutical Preparations
[Class : 5] Medicinal And Pharmaceutical Preparations
View +1306 more Brands for Akums Drugs And Pharmaceuticals Limited.
Charges
27 April 2010
Standard Chartered Bank
15 Crore
25 August 2006
State Bank Of India
60 Crore
24 March 2015
Standard Chartered Investments And Loans (india) Limited
30 Crore
26 March 2010
Standard Chartered Bank
25 Crore
21 August 2008
Icici Bank Limited
20 Crore
29 November 2006
Icici Bank Limited
20 Crore
25 August 2006
State Bank Of India
9 Crore
23 June 2008
Standard Chartered Bank
15 Crore
30 August 2004
State Bank Of India
13 Crore
30 August 2004
State Bank Of India
5 Crore
12 February 2021
Citi Bank N.a.
20 Crore
04 March 2020
Icici Bank Limited
55 Lak
03 February 2020
Oriental Bank Of Commerce Limited
22 Lak
08 February 2023
Sbicap Trustee Company Limited
0
15 July 2022
Yes Bank Limited
0
13 July 2022
The Hongkong And Shanghai Banking Corporation Limited
0
11 April 2022
Citi Bank N.a.
0
12 February 2021
Citi Bank N.a.
0
16 August 2021
Hdfc Bank Limited
0
27 April 2010
Standard Chartered Bank
0
04 March 2020
Others
0
03 February 2020
Others
0
25 August 2006
State Bank Of India
0
29 November 2006
Icici Bank Limited
0
23 June 2008
Standard Chartered Bank
0
21 August 2008
Icici Bank Limited
0
24 March 2015
Standard Chartered Investments And Loans (india) Limited
0
30 August 2004
State Bank Of India
0
26 March 2010
Standard Chartered Bank
0
30 August 2004
State Bank Of India
0
25 August 2006
State Bank Of India
0
08 February 2023
Sbicap Trustee Company Limited
0
15 July 2022
Yes Bank Limited
0
13 July 2022
The Hongkong And Shanghai Banking Corporation Limited
0
11 April 2022
Citi Bank N.a.
0
12 February 2021
Citi Bank N.a.
0
16 August 2021
Hdfc Bank Limited
0
27 April 2010
Standard Chartered Bank
0
04 March 2020
Others
0
03 February 2020
Others
0
25 August 2006
State Bank Of India
0
29 November 2006
Icici Bank Limited
0
23 June 2008
Standard Chartered Bank
0
21 August 2008
Icici Bank Limited
0
24 March 2015
Standard Chartered Investments And Loans (india) Limited
0
30 August 2004
State Bank Of India
0
26 March 2010
Standard Chartered Bank
0
30 August 2004
State Bank Of India
0
25 August 2006
State Bank Of India
0
08 February 2023
Sbicap Trustee Company Limited
0
15 July 2022
Yes Bank Limited
0
13 July 2022
The Hongkong And Shanghai Banking Corporation Limited
0
11 April 2022
Citi Bank N.a.
0
12 February 2021
Citi Bank N.a.
0
16 August 2021
Hdfc Bank Limited
0
27 April 2010
Standard Chartered Bank
0
04 March 2020
Others
0
03 February 2020
Others
0
25 August 2006
State Bank Of India
0
29 November 2006
Icici Bank Limited
0
23 June 2008
Standard Chartered Bank
0
21 August 2008
Icici Bank Limited
0
24 March 2015
Standard Chartered Investments And Loans (india) Limited
0
30 August 2004
State Bank Of India
0
26 March 2010
Standard Chartered Bank
0
30 August 2004
State Bank Of India
0
25 August 2006
State Bank Of India
0
Documents
Form DIR-12-04042021_signed
Form DPT-3-03042021_signed
Form PAS-6-31102020_signed
Optional Attachment-(1)-31102020
Form MR-1-23102020_signed
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -21102020
Copy of certificate by the Nomination and Remuneration Committee of the company, if any, to the effect that the remuneration is-21102020
Copy of shareholders resolution-21102020
Notice of resignation;-21102020
Evidence of cessation;-21102020
Form DIR-12-21102020_signed
Optional Attachment-(1)-21102020
Optional Attachment-(2)-21102020
Form DIR-12-06102020_signed
Optional Attachment-(2)-06102020
Optional Attachment-(3)-06102020
Declaration of the appointee director, Managing director, in Form No. DIR-2;-06102020
Form PAS-6-27082020_signed
Optional Attachment-(1)-27082020
Form MGT-14-19032020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-19032020
Instrument(s) of creation or modification of charge;-14032020
Form CHG-1-14032020_signed
CERTIFICATE OF REGISTRATION OF CHARGE-20200314
Form DPT-3-27022020-signed
Form CHG-1-18022020_signed
Instrument(s) of creation or modification of charge;-18022020
CERTIFICATE OF REGISTRATION OF CHARGE-20200218
Form MR-1-15122019_signed
Form DIR-12-15122019_signed
